Priming with <scp>DNA</scp> Enhances Considerably the Immunogenicity of <scp>hCG</scp> β‐<scp>LTB</scp> Vaccine

Nand, Kripa N.; Gupta, Jagdish C.; Panda, Amulya K.; Jain, Swatantra Kumar; Talwar, G.P.

doi:10.1111/aji.12388

Cited by 10 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our immunization protocol demands initially 3 primary immunizations with the vaccine. While priming thrice with proteinic version of the vaccine achieved fairly high titres employing MiP as adjuvant, priming twice with the DNA version of the vaccine at fortnightly interval followed by the 3rd primary injection of the protein version, generated higher antibody response (Figure 6) than priming thrice with only the proteinic vaccine [14]. It may be stated that DNA vaccine is cheaper to make and is thermostable at room temperature thus requiring no cold chain.…”

Section: Further Enhancement Of Antibody Response To the Recombinant ...mentioning

confidence: 99%

Making of Vaccines against Human Chorionic Gonadotrophin for Control of Fertility of Women without Impairment of Ovulation and Menstrual Regularity

Gp¹,

Cj²,

Nk³

et al. 2016

Reproductive Immunol Open Acc

View full text Add to dashboard Cite

Reviewed briefly is the development of a unique vaccine against hCG, which prevents unwanted pregnancy without blocking ovulation and disturbing menstrual regularity. A recombinant version of this vaccine, amenable to largescale production by industry, in both DNA and protein form has been made. Priming with DNA followed by protein improves further its immunogenicity. Mycobacterium indicus pranii (MiP), a cultivable non-pathogenic mycobacteria has been used in the recombinant vaccine as a potent adjuvant. MiP was developed as an immunotherapeutic vaccine against leprosy. It is approved by the Drugs Controller General of India and USFDA, and has many additional applications in treatment of tuberculosis, curing of ugly ano-genital warts and in prevention and treatment of some cancers.

show abstract

Section: Further Enhancement Of Antibody Response To the Recombinant ...mentioning

confidence: 99%

Making of Vaccines against Human Chorionic Gonadotrophin for Control of Fertility of Women without Impairment of Ovulation and Menstrual Regularity

Gp¹,

Cj²,

Nk³

et al. 2016

Reproductive Immunol Open Acc

View full text Add to dashboard Cite

show abstract

“…As the recombinant vaccine is first made in DNA form, followed by its expression as protein, we have tested in mice, the immunogenicity of the combined use of the DNA form of the vaccine for priming, followed by the protein version of the vaccine. This mode of immunization generates a higher antibody response in mice (Figure 5) [12], hence the adoption of this regime for the clinical trial.…”

Section: Resumption Of Clinical Trialmentioning

confidence: 99%

A unique vaccine for birth control and treatment of advanced stage cancers secreting ectopically human chorionic gonadotropin

Talwar¹,

Gupta²,

Purswani

et al. 2021

Explor Immunol

Self Cite

View full text Add to dashboard Cite

This article is a tribute and homage to Gerard Chaouat who invited me to contribute this article. My years in France have remained very memorable to me. Reviewed briefly is the vaccine that was made against human chorionic gonadotropin (hCG) to prevent unwanted pregnancy in sexually active women. It has now been developed as a genetically engineered recombinant vaccine and passed onto industry for its production under good manufacturing practices (GMP) conditions for confirmatory trials. The trials have received the approval of the Drugs Controller General of India. The trials have started but have been interrupted by the coronavirus disease 2019 (COVID-19) pandemic. This vaccine is likely to have another highly beneficial application in the treatment of cancers expressing ectopically hCG.

show abstract

Section: In Marmosetsmentioning

confidence: 99%

Current status of a unique vaccine preventing pregnancy

Talwar¹,

Nand²,

Gupta³

et al. 2017

Front Biosci

View full text Add to dashboard Cite

The ability of a vaccine linking beta hCG to a carrier to generate antibodies against hCG, its reversibility and safety was established by Phase I clinical trials conducted in India, Finland, Sweden, Chile and Brazil. Employing a hetero-species dimer (beta hCG-αoLH) linked to tetanus toxoid further improved the immunogenicity of the vaccine. Phase II clinical trials showed that anti-hCG titres above 50 ng/ml prevented pregnancy of sexually active fertile women without derangement of ovulation and menstrual regularity. On decline of antibodies, women conceived again to give birth to normal progeny. A genetically engineered vaccine consisting of beta hCG linked to B subunit of heat labile enterotoxin of E. coli has been made. It is expressed as DNA as well as protein. Priming with DNA followed by protein version of the vaccine generates very high titres against hCG in mice. Extensive toxicology studies in 2 species of rodents, and marmosets have shown complete safety of the vaccine. The vaccine is cleared for Clinical trials by the National Review committee on Genetic Manipulation and Drugs Controller General of India.

show abstract

Priming with DNA Enhances Considerably the Immunogenicity of hCG β‐LTB Vaccine

Abstract: Immunization with the DNA form of the recombinant hCGβ-LTB vaccine twice at fortnightly interval followed by the proteinic form of the vaccine induces distinctly higher antibody response.

Cited by 10 publications

References 20 publications

Making of Vaccines against Human Chorionic Gonadotrophin for Control of Fertility of Women without Impairment of Ovulation and Menstrual Regularity

Making of Vaccines against Human Chorionic Gonadotrophin for Control of Fertility of Women without Impairment of Ovulation and Menstrual Regularity

A unique vaccine for birth control and treatment of advanced stage cancers secreting ectopically human chorionic gonadotropin

Current status of a unique vaccine preventing pregnancy

Contact Info

Product

Resources

About